All In Biotech

Drug Trial Radar · NCT00862654

Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis

Efficacy and Safety of Clobetasol Propionate Shampoo 0.05% Used in Association With an Antifungal Shampoo in the Treatment of Moderate to Severe Scalp Seborrheic Dermatitis

Last checked: Nov 19, 2026Latest source record: Feb 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 326 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

326

Actual

Start

Mar 2009

Primary completion

Feb 2010

Study completion Feb 2010

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Mar 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective is to assess different treatment regimens with Clobetasol propionate shampoo 0.05% in the treatment of scalp Seborrheic Dermatitis.

Conditions

  • Scalp Seborrheic Dermatitis

Interventions

  • clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)Drug

    Association: clobetasol propionate shampoo \& ketoconazole shampoo

  • clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)Drug

    Association: clobetasol propionate shampoo \& ketoconazole shampoo

  • clobetasol propionate shampoo (2/week)Drug

    Monotherapy with clobetasol propionate shampoo

  • ketoconazole shampoo (2/week)Drug

    Monotherpay ketoconazole shampoo (2/week)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Severity Score (TSS): Percent Change From Baseline at Week 4Time frame: baseline and week 4

Locations

18 sites in 5 countries. Site status is shown where the registry gives one.

  • Galderma Investigational Center

    Bruges, Belgium

  • Galderma Investigational Center

    Brussels, Belgium

  • Galderma Investigational Center

    Geel, Belgium

  • Galderma Investigational Center

    Ghent, Belgium

  • Galderma Investigational Center

    Liège, Belgium

  • Galderma Investigational Center

    Mons, Belgium

  • Galderma Investigational Center

    Paris, France

  • Galderma Investigational Center

    Berlin, Germany

  • Galderma Investigational Center

    Bonn, Germany

  • Galderma Investigational Center

    Hamburg, Germany

  • Galderma Investigational Center

    Lübeck, Germany

  • Galderma Investigational Center

    Mahlow, Germany

  • Galderma Investigational Center

    Wuppertal, Germany

  • Galderma Investigational Center

    Guadalajara, Mexico

  • Galderma Investigational Center

    México, Mexico

  • Galderma Investigational Center

    Naucalpan, Mexico

  • Galderma Investigational Center

    Zapopan, Jalisco, Mexico

  • Galderma Investigational Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.